Equities

X4 Pharmaceuticals Inc

X4 Pharmaceuticals Inc

Actions
  • Price (EUR)0.85
  • Today's Change-0.027 / -3.08%
  • Shares traded2.50k
  • 1 Year change-46.54%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 16:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

  • Revenue in USD (TTM)0.00
  • Net income in USD-128.91m
  • Incorporated2010
  • Employees93.00
  • Location
    X4 Pharmaceuticals Inc61 NORTH BEACON STREET, 4TH FLOORBOSTON 02134United StatesUSA
  • Phone+1 (857) 529-8300
  • Fax+1 (302) 655-5049
  • Websitehttps://www.x4pharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.